Lynparza + abiraterone delay disease progression in men with mCRPC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

According to results from the PROpel phase III trial, Lynparza (olaparib) in combination with abiraterone had a significant positive effect on radiographic progression-free survival versus standard-of-care abiraterone as a first-line treatment for men with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

U.S. Deputy Secretary for Health and Human Services, Andrea Palm, and Sweden's Minister for Health Care, Acko Ankarberg Johansson, signing the agreement. Credit: Joel Apelthun/Government Offices of SwedenThe United States and Sweden signed an agreement to step up collaborations in science and technology by focusing on cancer research.

Login